Primary and secondary time-to-event outcomes for comparison of efavirenz plus emtricitabine-tenofovir-DF to efavirenz plus lamivudine-zidovudine using data collected through 31-May-2010.

aAlso known as relative risk. Estimated from Cox regression model stratified by both country and RNA stratum and including randomized treatment group as sole covariate.bp-Value calculated from stratified log-rank test between arms. Not applicable (NA) because no formal hypothesis testing was performed based on DSMB recommendations.cThe five most common causes of death were infection (17 deaths) and unknown cause (five deaths) followed by suicide, trauma, and stroke (three deaths each).dDisease progression diagnoses are in Table S7; grade 3 and 4 laboratory adverse events in Table S8; and signs and symptoms in Table S9.eAll events meeting these criteria are reported; some participants met criteria for multiple endpoints.fConfirmed plasma HIV RNA≥1,000 copies/ml at study week 16 or later.gChange in any component of initial randomized antiretroviral regimen.hThe following antiretroviral substitutions were prespecified and were not included in this endpoint: stavudine or TDF for ZDV, nevirapine for EFV, or didansoine for TDF.iCD4+ lymphocytes